NASDAQ$SMTI
Sanara MedTech Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Sanara MedTech announced record sales quarter driven by strong product sales and strategic initiatives.
Sanara MedTech reported a record sales quarter driven by strong product sales across a wider number of facilities and geographies. The company closed on the Pixalere partnership and completed the acquisition of certain assets of Rochal Industries, LLC.
- Sanara had another record sales quarter to end the first half of 2021.
- Results were driven by strong product sales across a wider number of facilities and geographies.
- The company continued to execute on its comprehensive wound and skin strategy by closing on the Pixalere partnership.
- Subsequent to the end of the quarter, Sanara completed the acquisition of certain assets of Rochal Industries, LLC.
Headline financials
Revenue & EPS history
Sanara MedTech · Revenue · Quarterly
$6.28M
Revenue by segment
Sanara MedTech · $31.6M total across 2 segments · Q2 2023
- Soft tissue repair$15.8M—50.0%
- Bone fusion products$15.8M—50.0%
Forward guidance
This press release contains forward-looking statements regarding anticipated benefits of the Rochal acquisition, the development of new products and expansion of the Company’s business in telehealth and wound care.
Tailwinds
- Anticipated benefits of the Rochal acquisition
- Development of new products
- Expansion of the Company’s business in telehealth
- Expansion of the Company’s business in wound care
Headwinds
- Sanara’s ability to successfully integrate the acquired business and operations of Rochal
- Sanara’s ability to retain key employees following the acquisition
- Unexpected costs or expenses that may result from the acquisition
- Uncertainties associated with the development and process for obtaining regulatory approval for new products
- The extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2021
+0.1%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.6%
Avg return
30 days after
34%
22 / 65 earnings
Positive
+28.6%
Q4 2014
Best reaction
-25.0%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.3% | -12.1% | — | |
| Q1 2026 | +13.0% | +17.3% | +19.5% | |
| Q3 2025 | -23.4% | -24.9% | -7.6% | |
| Q2 2025 | -4.8% | -3.3% | +6.4% | |
| Q1 2025 | -9.0% | -11.2% | -17.9% | |
| Q4 2024 | -12.6% | -15.4% | -10.4% | |
| Q3 2024 | +6.3% | -1.0% | +2.5% | |
| Q2 2024 | +14.9% | +16.3% | +20.2% | |
| Q1 2024 | -5.0% | -2.9% | -0.5% | |
| Q4 2023 | -1.8% | -1.1% | -13.1% | |
| Q3 2023 | +18.8% | +15.3% | +37.5% | |
| Q2 2023 | -12.5% | -13.6% | -22.6% | |
| Q1 2023 | -5.0% | -9.2% | -5.9% | |
| Q4 2022 | -0.1% | -4.1% | +17.9% | |
| Q3 2022 | +4.1% | +7.2% | +3.2% | |
| Q2 2022 | +1.2% | -1.7% | +13.4% | |
| Q1 2022 | +5.0% | +2.3% | -12.2% | |
| Q4 2021 | +2.5% | +10.7% | -10.9% | |
| Q3 2021 | -1.6% | -2.2% | -15.8% | |
| Q2 2021 | -8.3% | -12.4% | -14.5% | |
| Q1 2021 | +5.2% | +14.9% | +28.7% | |
| Q4 2020 | +14.5% | +6.8% | -4.5% | |
| Q3 2020 | -4.5% | -4.3% | +15.7% | |
| Q2 2020 | +9.8% | +13.7% | +37.2% | |
| Q1 2020 | -20.7% | -18.2% | +28.8% | |
| Q4 2019 | -4.3% | +7.3% | +30.9% | |
| Q3 2019 | -3.9% | -5.7% | +5.1% | |
| Q2 2019 | -11.5% | -20.1% | -17.2% | |
| Q1 2019 | +0.0% | -16.7% | -16.7% | |
| Q4 2018 | +0.0% | -16.7% | -16.7% | |
| Q3 2018 | +0.0% | +0.0% | +0.0% | |
| Q2 2018 | -10.0% | -10.0% | -30.0% | |
| Q1 2018 | +20.0% | +0.0% | +20.0% | |
| Q4 2017 | +20.0% | +0.0% | +20.0% | |
| Q3 2017 | +0.0% | +0.0% | -14.3% | |
| Q2 2017 | +0.0% | +16.7% | +16.7% | |
| Q1 2017 | +0.0% | +0.0% | -22.2% | |
| Q4 2016 | +0.0% | +0.0% | -10.0% | |
| Q3 2016 | -20.0% | -20.0% | +0.0% | |
| Q2 2016 | +20.0% | +0.0% | +0.0% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +11.1% | — | — | |
| Q4 2014 | +28.6% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +14.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +16.7% | — | — | |
| Q4 2012 | -12.5% | — | — | |
| Q3 2012 | -16.7% | — | — | |
| Q2 2012 | +6.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -10.3% | — | — | |
| Q1 2011 | -11.1% | — | — | |
| Q4 2010 | +3.1% | — | — | |
| Q3 2010 | -25.0% | — | — | |
| Q2 2010 | +2.9% | — | — | |
| Q1 2010 | +5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro